Back

Lipocine starts Phase 3 trial of oral brexanolone for postpartum depression

Verifying
  • Lipocine Inc. initiated the BLOOM Phase 3 trial evaluating LPCN 1154.
  • About 120 participants are planned for enrollment in the study.
  • LPCN 1154 aims to provide rapid relief for severe postpartum depression symptoms.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Lipocine starts Phase 3 trial of oral brexanolone for postpartum depression - CoinPost Terminal